Sort   by:  
 Page size 
ProteomicsEZH2 inhibition overcomes immunomodulatory drug (IMiD) resistance in multiple myeloma cell lines in a CRBN pathway dependent manner
Immunomodulatory agents (IMiDs) and the next-generation Cereblon (CRBN) E3 ligase modulators (CeLMoDs), targeting the Ikaros/Aiolos-IRF4-MYC axis, are effective therapies for multiple myeloma (MM) across all stages of disease. Resistance to treatment can be acquired following exposure, but a subset ...
ORGANISM(S): Homo sapiens (Human) 
2026-03-19 | PXD057933 | Pride
Ezh2 inhibition Myeloma Imid Crbn pathway 
UnknownLeveraging efficiency metrics for the optimization of CELMoDs™ as cereblon-based molecular glue degraders.
Not available
S-EPMC11876855 | biostudies-literature
TranscriptomicsMezigdomide is effective alone and in combination with Menin inhibition in pre-clinical models of KMT2A-r and NPM1c AML
To compare gene expression changes following treatment with two CELMoDs (cereblon E3 ligase modulators) in a Lysine Methyltransferase 2A-rearranged (KMT2A-r) acute myeloid leukemia cell line, we compared gene expression changes after 72 hour of treatment with Iberdomide/CC-220 and Mezigdomide/CC-924...
ORGANISM(S): Homo sapiens 
2024-02-20 | GSE232007 | GEO
ProteomicsiTAG an optimized IMiD-induced degron for targeted protein degradation in human and murine cells
To address the limitation associated with degron based systems, we have developed iTAG, a novel synthetic tag based on IMiDs/CELMoDs mechanism of action that improves and addresses the limitations of both PROTAC and previous IMiDs/CeLMoDs based tags. Using structural and sequence analysis, we system...
ORGANISM(S): Mus musculus (Mouse) 
2023-06-27 | PXD038299 | Pride
Lc-msms Imids Targeted protein degradation Protacs 
UnknowniTAG an optimized IMiD-induced degron for targeted protein degradation in human and murine cells.
Not available
S-EPMC10285648 | biostudies-literature
TranscriptomicsTargeting of IRAK4 and GSPT1 enhances therapeutic efficacy in AML via c-Myc destabilization
IRAK4 is a therapeutic target in myeloid malignancies, but current IRAK4 inhibitors show only modest clinical efficacy in acute myeloid leukemia (1), highlighting the need for combination strategies. To identify drugs with synergistic potential alongside IRAK4 inhibitors, we conducted a high-through...
ORGANISM(S): Homo sapiens 
2025-09-03 | GSE298391 | GEO
UnknownTargeting of IRAK4 and GSPT1 enhances therapeutic efficacy in AML via c-Myc destabilization.
Not available
S-EPMC12380595 | biostudies-literature
UnknownEvaluating the impact of CRBN mutations on response to immunomodulatory drugs and novel cereblon E3 ligase modulators in myeloma.
Not available
S-EPMC12824623 | biostudies-literature
UnknownUSP15 antagonizes CRL4CRBN-mediated ubiquitylation of glutamine synthetase and neosubstrates.
Not available
S-EPMC8501880 | biostudies-literature
OtherIMiD/CELMoD resistance in myeloma is associated with changes in lipid metabolism that may be targetable
Immunomodulatory drugs (IMiDs) are a cornerstone of multiple myeloma treatment and newer cereblon E3 ligase modulating drugs (CELMoDs) are in clinical trials. However, a major barrier to improving patient outcomes is the inevitable development of resistance to these agents. To explore the mechanisms...
ORGANISM(S): Homo sapiens 
2026-09-28 | GSE346972 | GEO
Sort   by:  
 Page size